Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5843-5859

  Lu, Chuanjun ^a   Guo, Yueyan ^a   Yan, Jun ^a   Luo, Zonghua ^a   Luo, Hai Bin ^a   Yan, Ming ^a   Huang, Ling ^a   Li, Xingshu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 4 (DIMETHYLAMINO)PHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 4 (ISOBUTYLAMINO)PHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 4 (ISOPROPYLAMINO)PHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 4 (PROPYLAMINO)PHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 4 NITROPHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 5 METHOXYPHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] 6 METHOXYPHENOL; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL] N,N DIMETHYLANILINE; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL]PHENOL; 3 [[4 (3,5 DIHYDROXYSTYRYL)PHENYLAMINO]METHYL]BENZENE 1,2 DIOL; 4 (3,5 DIMETHOXYSTYRYL) N (2 METHOXYBENZYL)ANILINE; 4 (4 AMINOSTYRYL) N,N DIMETHYLANILINE; 4 (4 METHOXYSTYRYL)ANILINE; 4 (DIMETHYLAMINO) 2 [[4 (4 METHOXYSTYRYL)PHENYLAMINO]METHYL]PHENOL; 4 (DIMETHYLAMINO) 2 [[4 [4 (DIMETHYLAMINO)STYRYL] PHENYLAMINO]METHYL]PHENOL; 4 AMINO 2 [(4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL]PHENOL; 4 CHLORO 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYLAMINO]METHYL]PHENOL; 5 [4 (2 HYDROXY 5 NITROBENZYLAMINO)STYRYL]BENZENE 1,3 DIOL; 5 [4 (2 HYDROXYBENZYLAMINO)STYRYL]BENZENE 1,3 DIOL; 5 [4 [2 (DIMETHYLAMINO)BENZYLAMINO]STYRYL]BENZENE 1,3 DIOL; 5 [4 [5 (DIMETHYLAMINO) 2 HYDROXYBENZYLAMINO]STYRYL]BENZENE 1,3 DIOL; CLIOQUINOL; CURCUMIN; N [(1H INDOL 3 YL)METHYL] 4 (3,5 DIMETHOXYSTYRYL)ANILINE; N [(1H PYRROL 3 YL)METHYL] 4 (3,5 DIMETHOXYSTYRYL)ANILINE; RESVERATROL; RESVERATROL DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; CHOLINESTERASE INHIBITORS; CLIOQUINOL; DRUG DESIGN; HUMANS; MICE; MONOAMINE OXIDASE INHIBITORS; PEPTIDE FRAGMENTS; STILBENES;

EID: 84880915278     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400567s     Document Type: Article

References (57)

1. Finder, V. H. Alzheimer's disease: a general introduction and pathomechanism J. Alzheimer's Dis. 2010, 22, 5-19
2. Roberson, E. D.; Mucke, L. 100 years and counting: prospects for defeating Alzheimer's disease Science 2006, 314, 781-784
3. Pepeu, G.; Giovannini, M. G. Cholinesterase inhibitors and beyond Curr. Alzheimer Res. 2009, 6, 86-96
4. Rampa, A.; Bartolini, M.; Bisi, A.; Belluti, F.; Gobbi, S.; Andrisano, V.; Ligresti, A.; Di Marzo, V. The first dual che/faah inhibitors: new perspectives for Alzheimer's disease? ACS Med. Chem. Lett 2012, 3, 182-186
5. Hardy, J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J. Neurochem. 2009, 110, 1129-1134
6. Salomone, S.; Caraci, F.; Leggio, G. M.; Fedotova, J.; Drago, F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Br. J. Clin. Pharmacol. 2012, 73, 504-517
7. Bonda, D. J.; Wang, X.; Perry, G.; Nunomura, A.; Tabaton, M.; Zhu, X.; Smith, M. A. Oxidative stress in Alzheimer disease: a possibility for prevention Neuropharmacology 2010, 59, 290-294
8. Bush, A. I. Drug development based on the metals hypothesis of Alzheimer's disease J. Alzheimer's Dis. 2008, 15, 223-240
9. Huang, X.; Atwood, C. S.; Hartshorn, M. A.; Multhaup, G.; Goldstein, L. E.; Scarpa, R. C.; Cuajungco, M. P.; Gray, D. N.; Lim, J.; Moir, R. D.; Tanzi, R. E.; Bush, A. I. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 1999, 38, 7609-7616
10. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease J. Neurochem. 2003, 87, 172-181
11. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. Drug Discovery 2006, 5, 493-506
12. Abraham, J.; Johnson, R. W. Consuming a diet supplemented with resveratrol reduced infection-related neuroin-flammation and deficits in working memory in aged mice Rejuvenation Res. 2009, 12, 445-453
13. Oomen, C. A.; Farkas, E.; Roman, V.; van der Beek; Eline, M.; Luiten, P. G. M.; Meerlo, P. Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front. Aging Neurosci. 2009, DOI: 10.3389/neuro.24.004. 2009.
14. Smoliga, J. M.; Baur, J. A.; Hausenblas, H. A. Resveratrol and health-a comprehensive review of human clinical trials Mol. Nutr. Food Res. 2011, 55, 1129-1141
15. 1-42 aggregation inhibitors, antioxidants, and neuroprotective agents Bioorg. Med. Chem. Lett. 2012, 22, 7683-7687
16. Atwood, C. S.; Moir; Robert, D.; Huang, X.; Scarpa, R. C.; Bacarra, N.; Michael, E.; Romano, D. M.; Hartshorn, M. A.; Tanzi, R. E.; Bush, A. I. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis J. Biol. Chem. 1998, 273, 12817-12826
17. Atwood, C. S.; Scarpa, R. C.; Huang, X.; Moir, R. D.; Jones, W. D.; Fairlie, D. P.; Tanzi, R. E.; Bush, A. I. Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar-affinity copper binding site on amyloid β 1-42 J. Neurochem. 2000, 75, 1219-1233
18. Curtain, C. C.; Ali, F.; Volitakis, I.; Cherny, R. A.; Norton, R. S.; Beyreuther, K.; Barrow, C. J.; Masters, C. L.; Bush, A. I.; Barnham, K. J. Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits J. Biol. Chem. 2001, 276, 20466-20473
19. Huang, X.; Moir, R. D.; Tanzi, R. E.; Bush, A. I.; Rogers, J. T. Redox-active metals, oxidative stress, and Alzheimer's disease pathology Ann. N.Y. Acad. Sci. 2004, 1012, 153-156
20. Rogers, J. T.; Lahiri, D. K. Metal and inflammatory targets for Alzheimer's disease Curr. Drug Targets 2004, 5, 535-551
21. Ritchie, C. W.; MRCPsych, M. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch. Neurol. 2003, 60, 1685-1691
22. Roher, A. E.; Lowenson, J. D.; Clarke, S.; Woods, A. S.; Cotter, R. J.; Gowing, E.; Ball, M. J. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10836-10840
23. Mayeux, R.; Tang, M.; Jacobs, J. D. M.; Manly, J.; Bell, K.; Merchant, C.; Small, S. A.; Stern, Y.; Wisniewski, H. M.; Mehta, P. D. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease Ann. Neurol. 1999, 46, 412-416
24. Varadarajan, S.; Kanski, J.; Aksenova, M.; Lauderback, C.; Butterfield, D. A. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta (1-42) and A beta (25-35) J. Am. Chem. Soc. 2001, 123, 5625-5631
25. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDR receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 2008, 51, 4381-4384
26. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 2001, 49, 4619-4626
27. Dávalos, A.; Gómez-Cordovés, C.; Bartolomé, B. Extending applicability of the oxygen radical absorbance capacity (orac-fluorescein) assay J. Agric. Food Chem. 2003, 52, 48-54
28. Behl, C.; Davis, J. B.; Lesley, R.; Schubert, D. Hydrogen peroxide mediates amyloid β protein toxicity Cell 1994, 77, 817-827
29. 25-35 region to aggregation and neurotoxicity J. Neurochem. 1995, 64, 253-265
30. Lorenzo, A.; Yankner, B. A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congored Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12243-12447
31. Soto, C.; Castano, E. M.; Kumar, R. A.; Beavis, R.; Frangione, C. B. Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure Neurosci. Lett. 1995, 200, 105-108
32. Wang, S. S.; Chen, Y. T.; Chou, S. W. Inhibition of amyloid fibril formation of β-amyloid peptides via the amphiphilic surfactants Biochim. Biophys. Acta 2005, 1741, 307-313
33. Andrew, J. D. Peptide inhibitors of β-amyloid aggregation Curr. Opin. Drug Discovery Dev. 2007, 10, 533-539
34. Yang, C.; Zhu, X.; Li, J.; Shi, R. Exploration of the mechanism for LPFFD inhibiting the formation of β-sheet conformation of Aβ (1-42) in water J. Mol. Model. 2010, 16, 813-821
35. Crescenzi, O.; Tomaselli, S.; Guerrini, R.; Salvadori, S.; D'Ursi, A. M.; Temussi, P. A.; Picone, D. Solution structure of the Alzheimer amyloid β-peptide (1-42) in an apolar microenvironment Eur. J. Biochem. 2002, 269, 5642-5648
36. 42 peptide J. Am. Chem. Soc. 2012, 134, 6625-6636
37. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models J. Alzheimer's Dis. 2004, 6, 367-377
38. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease J. Med. Chem. 2007, 50, 6446-6449
39. Geng, J.; Li, M.; Wu, L.; Ren, J.; Qu, X. Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment J. Med. Chem. 2012, 55, 9146-9155
40. + in aqueous solution and live cells Dalton Trans. 2012, 41, 7212-7217
41. Gil, V. M. S.; Oliveira, N. C. On the use of the method of continuous variations J. Chem. Educ. 1990, 67, 473-478
42. Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y.; Vivekanandan, S.; Ramamoorthy, A.; Lim, M. H. Small molecule modulators of copper-induced Aβ aggregation J. Am. Chem. Soc. 2009, 131, 16663-16665
43. Weyler, W.; Hsu, Y.-P. P.; Breakafield, X. O. Biochemistry and genetics of monoamine oxidase Pharmacol. Ther. 1990, 47, 391-417
44. Riederer, P.; Danielczyk, W.; Grünblatt, E. Monoamine oxidase-b inhibition in Alzheimer's disease Neurotoxicology 2004, 25, 271-277
45. Bolea, I.; Juárez-Jiménez, J.; de los Ríos, C.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N -[(5-(benzyloxy)-1-methyl-1 H -indol-2-yl)methyl]- N -methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease J. Med. Chem. 2011, 54, 8251-8270
46. Oyama, Y.; Hayashi, A.; Ueha, T.; Maekawa, K. Characterization of 2′,7′-dichlorofluorescin fluorescence in dissociated mammalian brain neurons: estimation on intracellular content of hydrogen peroxide Brain Res. 1994, 635, 113-117
47. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
48. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N. s.; Lavilla, R.; Badia, A.; Clos, M. V. r.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Huertas, O. s.; Dafni, T.; Luque, F. J. Pyrano[3,2- c ]quinoline-6-Chlorotacrine hybrids as a novel family of acetylcholinesterase- and β-amyloid-directed anti-Alzheimer compounds J. Med. Chem. 2009, 52, 5365-5379
49. Wohnsland, F.; Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes J. Med. Chem. 2001, 44, 923-930
50. Liu, H.; Dong, A.; Gao, C.; Tan, C.; Liu, H.; Zu, X.; Jiang, Y. The design, synthesis, and anti-tumor mechanism study of N -phosphoryl amino acid modified resveratrol analogues Bioorg. Med. Chem. 2008, 16, 10013-10021
51. Choi, J.-S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Design of small molecules that target metal-aβ species and regulate metal-induced Aβ aggregation and neurotoxicity Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 21990-21995
52. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 2005, 49, 459-462
53. Decker, M.; Kraus, B.; Heilmann, J. Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties Bioorg. Med. Chem. 2008, 16, 4252-4261
54. Fernández-Bachiller, M. a. I.; Pérez, C. n.; González-Muñoz, G. C.; Conde, S.; López, M. G.; Villarroya, M.; García, A. G.; Rodríguez-Franco, M. a. I. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties J. Med. Chem. 2010, 53, 4927-4937
55. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
56. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63
57. Cao, R.; Chen, Q.; Hou, X.; Chen, H.; Guan, H.; Ma, Y.; Peng, W.; Xu, A. Synthesis, acute toxicities, and antitumor effects of novel 9-substituted β-carboline derivatives Bioorg. Med. Chem. 2004, 12, 4613-4623